Pharmacometabonomic phenotyping reveals different responses to xenobiotic intervention in rats

Houkai Li, Yan Ni, Mingming Su, Yunping Qiu, Mingmei Zhou, Mingfeng Qiu, Aihua Zhao, Liping Zhao, Wei Jia

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

In conventional pharmacological studies, intersubject differences within an animal strain are normally neglected, leading to variations in pharmacological outcomes in response to the same stimulus. Using two classical experimental models, the Streptozotocin (STZ)-induced diabetic model of Wistar rats and the high-energy, diet-induced obesity model of Sprague-Dawley rats, we demonstrate that the different outcomes of STZ or diet intervention are closely associated with variation in predose (baseline) urinary metabolic profiles of the rats. The pharmacometabonomic analysis of predose metabolic profiles indicates that the intersubject difference is, to a great extent, associated with gut-microbiota, which predisposes different pathophysiological outcomes upon diet alteration or chemical stimulus. We hypothesize that there may exist an important association between observations from these two models and the obese/diabetic human population in that subtle variations in metabolic phenotype may predetermine different systems' responses to xenobiotic perturbation, ultimately leading to varied pathophysiological processes. Results from two independent models also suggest that the pharmacometabonomics approach is of great importance in the study of pharmacology and clinical drug evaluations, where endogenous metabolite signatures of predose individuals should be taken into consideration to minimize intersubject difference and the resulting variation in the postdose pharmacological outcomes.

Original languageEnglish (US)
Pages (from-to)1364-1370
Number of pages7
JournalJournal of Proteome Research
Volume6
Issue number4
DOIs
StatePublished - Apr 2007
Externally publishedYes

Fingerprint

Xenobiotics
Rats
Metabolome
Pharmacology
Streptozocin
Diet
Nutrition
Drug Evaluation
Clinical Pharmacology
Sprague Dawley Rats
Wistar Rats
Theoretical Models
Obesity
Phenotype
Metabolites
Animals
Population
Pharmaceutical Preparations

Keywords

  • GC/MS
  • Intersubject difference
  • Metabolic phenotyping
  • Pharmacometabonomics
  • Predose metabolic profile
  • Xenobiotic intervention

ASJC Scopus subject areas

  • Genetics
  • Biotechnology
  • Biochemistry

Cite this

Pharmacometabonomic phenotyping reveals different responses to xenobiotic intervention in rats. / Li, Houkai; Ni, Yan; Su, Mingming; Qiu, Yunping; Zhou, Mingmei; Qiu, Mingfeng; Zhao, Aihua; Zhao, Liping; Jia, Wei.

In: Journal of Proteome Research, Vol. 6, No. 4, 04.2007, p. 1364-1370.

Research output: Contribution to journalArticle

Li, Houkai ; Ni, Yan ; Su, Mingming ; Qiu, Yunping ; Zhou, Mingmei ; Qiu, Mingfeng ; Zhao, Aihua ; Zhao, Liping ; Jia, Wei. / Pharmacometabonomic phenotyping reveals different responses to xenobiotic intervention in rats. In: Journal of Proteome Research. 2007 ; Vol. 6, No. 4. pp. 1364-1370.
@article{02e9ba9a7c394812ac80f678c6ddd229,
title = "Pharmacometabonomic phenotyping reveals different responses to xenobiotic intervention in rats",
abstract = "In conventional pharmacological studies, intersubject differences within an animal strain are normally neglected, leading to variations in pharmacological outcomes in response to the same stimulus. Using two classical experimental models, the Streptozotocin (STZ)-induced diabetic model of Wistar rats and the high-energy, diet-induced obesity model of Sprague-Dawley rats, we demonstrate that the different outcomes of STZ or diet intervention are closely associated with variation in predose (baseline) urinary metabolic profiles of the rats. The pharmacometabonomic analysis of predose metabolic profiles indicates that the intersubject difference is, to a great extent, associated with gut-microbiota, which predisposes different pathophysiological outcomes upon diet alteration or chemical stimulus. We hypothesize that there may exist an important association between observations from these two models and the obese/diabetic human population in that subtle variations in metabolic phenotype may predetermine different systems' responses to xenobiotic perturbation, ultimately leading to varied pathophysiological processes. Results from two independent models also suggest that the pharmacometabonomics approach is of great importance in the study of pharmacology and clinical drug evaluations, where endogenous metabolite signatures of predose individuals should be taken into consideration to minimize intersubject difference and the resulting variation in the postdose pharmacological outcomes.",
keywords = "GC/MS, Intersubject difference, Metabolic phenotyping, Pharmacometabonomics, Predose metabolic profile, Xenobiotic intervention",
author = "Houkai Li and Yan Ni and Mingming Su and Yunping Qiu and Mingmei Zhou and Mingfeng Qiu and Aihua Zhao and Liping Zhao and Wei Jia",
year = "2007",
month = "4",
doi = "10.1021/pr060513q",
language = "English (US)",
volume = "6",
pages = "1364--1370",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - Pharmacometabonomic phenotyping reveals different responses to xenobiotic intervention in rats

AU - Li, Houkai

AU - Ni, Yan

AU - Su, Mingming

AU - Qiu, Yunping

AU - Zhou, Mingmei

AU - Qiu, Mingfeng

AU - Zhao, Aihua

AU - Zhao, Liping

AU - Jia, Wei

PY - 2007/4

Y1 - 2007/4

N2 - In conventional pharmacological studies, intersubject differences within an animal strain are normally neglected, leading to variations in pharmacological outcomes in response to the same stimulus. Using two classical experimental models, the Streptozotocin (STZ)-induced diabetic model of Wistar rats and the high-energy, diet-induced obesity model of Sprague-Dawley rats, we demonstrate that the different outcomes of STZ or diet intervention are closely associated with variation in predose (baseline) urinary metabolic profiles of the rats. The pharmacometabonomic analysis of predose metabolic profiles indicates that the intersubject difference is, to a great extent, associated with gut-microbiota, which predisposes different pathophysiological outcomes upon diet alteration or chemical stimulus. We hypothesize that there may exist an important association between observations from these two models and the obese/diabetic human population in that subtle variations in metabolic phenotype may predetermine different systems' responses to xenobiotic perturbation, ultimately leading to varied pathophysiological processes. Results from two independent models also suggest that the pharmacometabonomics approach is of great importance in the study of pharmacology and clinical drug evaluations, where endogenous metabolite signatures of predose individuals should be taken into consideration to minimize intersubject difference and the resulting variation in the postdose pharmacological outcomes.

AB - In conventional pharmacological studies, intersubject differences within an animal strain are normally neglected, leading to variations in pharmacological outcomes in response to the same stimulus. Using two classical experimental models, the Streptozotocin (STZ)-induced diabetic model of Wistar rats and the high-energy, diet-induced obesity model of Sprague-Dawley rats, we demonstrate that the different outcomes of STZ or diet intervention are closely associated with variation in predose (baseline) urinary metabolic profiles of the rats. The pharmacometabonomic analysis of predose metabolic profiles indicates that the intersubject difference is, to a great extent, associated with gut-microbiota, which predisposes different pathophysiological outcomes upon diet alteration or chemical stimulus. We hypothesize that there may exist an important association between observations from these two models and the obese/diabetic human population in that subtle variations in metabolic phenotype may predetermine different systems' responses to xenobiotic perturbation, ultimately leading to varied pathophysiological processes. Results from two independent models also suggest that the pharmacometabonomics approach is of great importance in the study of pharmacology and clinical drug evaluations, where endogenous metabolite signatures of predose individuals should be taken into consideration to minimize intersubject difference and the resulting variation in the postdose pharmacological outcomes.

KW - GC/MS

KW - Intersubject difference

KW - Metabolic phenotyping

KW - Pharmacometabonomics

KW - Predose metabolic profile

KW - Xenobiotic intervention

UR - http://www.scopus.com/inward/record.url?scp=34248139693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248139693&partnerID=8YFLogxK

U2 - 10.1021/pr060513q

DO - 10.1021/pr060513q

M3 - Article

VL - 6

SP - 1364

EP - 1370

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 4

ER -